AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03389217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real-tDCS + rehabilitation programme
Description: tDCS stimulation will be delivered using a constant current stimulator, with rechargeable batteries. The active electrode will be placed on the left dorsolateral prefrontal cortex (DLPFC) and the reference electrode will be placed over the controlateral supraorbital region. The direct current will be delivered through a pair of sponge electrodes with a surface of 35 cm2 (7 × 5), soaked in saline solution. This continuous stimulation will last 30 minutes, with an intensity of 1 mA. Rehabilitation programme will last for 30 minutes and includes specific exercises for prevention and management of pain. All the subjects enrolled will receive treatments for 4 weeks. During the first week the experimental group underwent tDCS daily (Monday-Friday) and rehabilitation programme 3 days per week. tDCS will be delivered before rehabilitation treatment. During the second, third and fourth week subjects will receive only rehabilitation treatment, 3 days per week.
Study NCT03389217 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham-tDCS + rehabilitation programme
Description: The control group will receive the same protocol treatment but they underwent sham-tDCS during the first week of treatment. For sham condition tDCS, current was delivered for only 30 seconds and then the current was discontinued, but the tDCS apparatus was left in place for the same time as active tDCS (30 minutes)
Study NCT02964442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsinoids
Description: 12 mg of Gel capsules
Study NCT02964442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Stimulus
Description: Cooling vest maintain at 14 degree Celsius
Study NCT01795846 — intervention group
Intervention type: OTHER
Intervention: Allergen specific immunotherapy and placebo injections
Study NCT03853993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent influenza vaccine
Description: Received single dose QIV (15µg/0.5ml)
Study NCT03853993 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Victoria strain)
Description: Received single dose TIV which contains B/Victoria strain (15µg/0.5ml)
Study NCT03853993 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine (contains B/Yamagata strain)
Description: Received single dose TIV which contains B/Yamagata strain (15µg/0.5ml)
Study NCT00167414 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Body Radiation Therapy
Description: Hypofractionated Stereotactic Body Radiation Therapy
Study NCT02567461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg
Description: Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
Study NCT01196832 — intervention group
Intervention type: PROCEDURE
Intervention: blood sample
Description: blood sample for fibrocytes analysis
Study NCT01196832 — intervention group
Intervention type: PROCEDURE
Intervention: Clinical and functional evaluation
Description: Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
Study NCT00848783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Study NCT00848783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT00848783 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT00167414 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Stereotactic Body Radiation Therapy
Description: Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
Study NCT05058599 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DM
Description: A new technology based on 3D reconstruction and deep learning algorithm to irreversibly erase the biometric attributes whilst retaining the clinical attributes needed for diagnosis and management
Study NCT03256591 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HBB facilitators with simulation training
Description: HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
Study NCT00848783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Floxuridine
Study NCT00848783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study NCT03878784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imigran
Description: All patients will undergo this intervention on one of two study days
Study NCT03878784 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Saline
Description: All patients will undergo this intervention on one of two study days
Study NCT00825812 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
Study NCT00825812 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine
Description: After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
Study NCT03360474 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delirium Screen
Description: Patients who screen positive for delirium will be assessed for pain, electrolyte imbalances,infection, the use of deliriogenic medications and any issues will be resolved. Those with persistent delirium following all other intervention will be treated with antipsychotic medication.
Study NCT03075358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine spray
Description: Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
Study NCT03075358 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal saline spray
Description: 0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
Study NCT02956798 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiation (SABR)
Description: SAbR treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions.
Study NCT05002491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein diet
Description: Normal vs high protein dietary feeding
Study NCT02360228 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tACS (alpha)
Study NCT02360228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS (alpha)
Study NCT02360228 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT02095080 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine intake
Description: Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
Study NCT01680744 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
Study NCT00307203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion SR
Description: Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
Study NCT00307203 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
Study NCT00307203 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Group Therapy
Description: Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
Study NCT00307203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine replacement therapy
Description: Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
Study NCT00307203 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine replacement therapy
Description: Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
Study NCT02059603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study NCT02059603 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fast-track program
Study NCT01429181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-racemic mixture of methadone HCl
Description: Non-racemic mixture of methadone HCl capsules, 5 mg
Study NCT01429181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-racemic mixture of methadone HCl
Description: Non-racemic mixture of methadone HCl capsules, 5 mg
Study NCT03528265 — intervention group
Intervention type: DEVICE
Intervention: Lateral flow immunoassay
Description: Biospecimens of patients with melioidosis-like symptoms will be tested with lateral flow immunoassay to detect Burkholderia pseudomallei, bacterium causing melioidosis
Study NCT01652040 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resistance Training and Testosterone Patches
Description: We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
Study NCT01652040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Patches
Description: The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
Study NCT01593761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CG400549
Description: 960mg QD at fed state approx 1 hour after meal
Study NCT05765994 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Modified hydrogen breath test
Description: A modified technique to obtain expired hydrogen from the ventilator tubes is performed. A connection with a valve attached to a collecting bag is inserted at the end of the expiratory limb of the breathing circuit for exhaled air collection.
Study NCT05361005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDB-001 injection
Description: Intravenous injection
Study NCT05361005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous injection
Study NCT01090648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine
Description: One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
Study NCT02059473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator cuff repair
Description: Physiotherapy \& Surgery
Study NCT02059473 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT02059473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study NCT01188304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: repeated daily doses
Study NCT01188304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: repeated daily doses
Study NCT01188304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: aspirin
Description: repeated daily doses
Study NCT01188304 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: repeated daily doses
Study NCT01667653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic capsule once daily
Study NCT01667653 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule once daily
Study NCT03662516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-04965842
Description: Orally bioavailable small molecule that selectively inhibits JAK 1 by blocking the adenosine triphosphate (ATP) binding site.
Study NCT03662516 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ethinyl estradiol (EE) and levonorgestrel (LN)
Description: Single dose of Oral tablet containing 30 ug EE and 150 ug of LN
Study NCT02444325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group prenatal care
Description: Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
Study NCT02486393 — intervention group
Intervention type: PROCEDURE
Intervention: Parotid surgery
Description: Surgery of the parotid gland tumours
Study NCT01965600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 125 mg, TID, 3 days, 1 of 2 periods
Study NCT01965600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, TID, 3 days, 1 of 2 periods
Study NCT01965600 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LPS
Description: IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
Study NCT04024436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib
Description: Futibatinib 20mg once daily on a 28 day cycle
Study NCT01406977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Study NCT04024436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Futibatinib plus Fulvestrant
Description: Futibatinib 20mg once daily and 500 mg fulvestrant administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond on a 28-day cycle.
Study NCT04352023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Description: Intravenous patient-controlled analgesia Patient-controlled epidural analgesia
Study NCT04342117 — intervention group
Intervention type: DRUG
Intervention: duvelisib
Description: 25 mg BID, 15 mg BID
Study NCT04342117 — intervention group
Intervention type: DRUG
Intervention: PI3K inhibitor
Description: FDA approved PI3K inhibitors
Study NCT01737216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus EP/TP
Description: Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
Study NCT01737216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EP/TP
Description: Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
Study NCT02776059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care + pegfiltrastim
Description: prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
Study NCT02776059 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Oral prednisolone or pentoxifyline for 28 days only
Study NCT00976833 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standardized Rehabilitation
Description: 3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
Study NCT02312726 — intervention group
Intervention type: PROCEDURE
Intervention: Postplacental IUD insertion
Description: Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
Study NCT01965600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06282999
Description: Tablet, 500 mg, BID, 3 days, 1 of 2 periods
Study NCT01965600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, 0 mg, BID, 3 days, 1 of 2 periods
Study NCT01435291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf Capsule
Description: Other Names:~* FK506E~* MR4~* tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
Study NCT01435291 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf Capsule
Description: Other Names:~* FK506E~* MR4~* tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent
Study NCT01223144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iowa Gambling Task and Ekman facial recognition test
Description: Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger).
Study NCT01223144 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Iowa Gambling Task and Ekman facial recognition test
Description: Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).~Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger).
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 1
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 2
Study NCT01529424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS apoC-III Rx
Description: Dose 3
Study NCT04371406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine and Azithromycin
Description: Hydroxychloroquine sulfate (PLAQUENIL®), 200mg x 3 /d, for 10 days AND Azithromycin (ZITHROMAX®), 500mg on D1 and then 250mg/d for the next 4 days, in addition to standard of care
Study NCT04371406 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Azinc
Description: Dietetary supplement, Azinc form and vitality®, 2 capsules per day, for 10 days, in addition to standard of care
Study NCT03709225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-based meditation
Description: The program is designed to incorporate music-based meditation practices and music making activities (e.g., guitar, drums) to help promote relaxation during cancer treatment
Study NCT00976833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Physical Therapy care
Study NCT01166425 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium Carbonate
Description: Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing \< 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
Study NCT01166425 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
Study NCT02800525 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond laser
Description: Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.